News | News By Subject | News by Disease News By Date | Search News

Leukemia [Chronic lymphocytic leukemia (CLL)] News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
FDA Orders 6 Partial or Full Clinical Holds on Celgene (CELG)'s Blood Cancer Studies     9/8/2017
Verastem (VSTM) Soars as Blood Cancer Drug Succeeds in Phase III Study     9/7/2017
Spectacular Data Posted for Novartis AG (NVS)'s Next Generation CAR-T Drug     6/2/2017
Juno (JUNO) Halts CAR-T Trial for Second Time Following Additional Patient Deaths     11/28/2016
Cancer Drug Developed by Eliza Hall Institute, AbbVie (ABBV) and Genentech (RHHBY) “Melts Away Cancer”     9/7/2016
Good News for Gilead (GILD) as Zydelig Passes Safety Review Test Despite Trial Deaths     7/12/2016
Infinity Pharma (INFI) Cuts Jobs by 58% as AbbVie (ABBV) Terminates Duvelisib Collaboration Deal     6/30/2016
FDA Green Lights AbbVie (ABBV), Genentech (RHHBY)'s New Chronic Lymphocytic Leukemia Drug Venclexta     4/12/2016
FDA Scorns Eagle Pharma (EGRX)'s Seven Year Orphan Drug Exclusivity Request for Blood Cancer Drug BENDEKA     3/28/2016
AbbVie (ABBV) and Roche (RHHBY)'s Venetoclax Snags Breakthrough Tag from the FDA for Blood Cancer     1/20/2016
Genentech (RHHBY) Touts Hematology Data for Gazyva and Venetoclax in CLL     12/17/2015
AbbVie (ABBV) Reveals Positive CLL Data at American Society of Hematology     12/7/2015
Genentech (RHHBY), AbbVie (ABBV) Confirm Venetoclax Met Primary Endpoint in Phase II Study     8/13/2015
AbbVie (ABBV), Genentech (RHHBY) Leukemia Drug Wins Breakthrough Status Tag     5/11/2015
AbbVie (ABBV) Elated as Pharmacyclics (PCYC)'s Imbruvica Shines in Combo Trial     3/20/2015

News from Around the Web
While Amgen (AMGN)-Size Biotechs Run Into Trouble, These Are The Biotechs With The Most Promising Pipelines     6/19/2017
Rituximab and Fludarabine Produce Long-Term Remissions in Some Chronic Lymphocytic Leukemia Patients, Ohio State University Study Suggests     3/1/2011
Rituximab Ups Survival in Chronic Lymphocytic Leukemia (CLL), University of Cologne Study     10/1/2010
Stem Cell Transplantation Successfully Treats Therapy-Resistant Chronic Leukemia, Heidelberg University Hospital Study Finds     7/13/2010
Complete Response with Oblimersen Combination Improves Survival of CLL Patients, M. D. Anderson Cancer Center Study     12/10/2007
Weizmann Institute of Science Scientists Discover: A Survival Mechanism for Blood Cancer Cells     8/28/2007
'Modular' Leukemia Drug Shows Promise in Early Testing, Ohio State University Study     6/29/2007
New Lymphocytic Leukemia Treatment Found     2/16/2007
Pair Of MicroRNA Molecules Controls Major Oncogene In Most Common Leukemia     12/15/2006
The Day In Review: Genasense Gets Negative FDA Report     9/5/2006
Mouse Mimics Chronic Leukemia, Will Aid Drug Development     8/23/2006
Gene Profile Predicts Leukemia's Course     10/27/2005

Press Releases
AbbVie (ABBV) Announces Positive Topline Results From Phase III Trial Evaluating VENCLEXTA/VENCLYXTO (Venetoclax) Tablets In Combination With Rituxan (Rituximab) For The Treatment Of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia     9/18/2017
TG Therapeutics (TGTX) Announces Completion Of Target Enrollment In The UNITY-CLL Phase III Trial     9/5/2017
Sunesis (SNSS) Announces First Patient Dosed In Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-Inhibitor SNS-062 In Adults With Chronic Lymphocytic Leukemia And Other B-Cell Malignancies     7/19/2017
Novartis AG (NVS) Pivotal CTL019 6-Month Follow-Up Data Show Durable Remission Rates In Children, Young Adults With R/R B-Cell ALL     6/23/2017
TG Therapeutics (TGTX) Announces Follow-Up Data For Combination Of TGR-1202 (Umbralisib) Plus Ibrutinib In Patients With Relapsed Or Refractory CLL And MCL At The 14th International Conference On Malignant Lymphoma     6/14/2017
BeiGene (BGNE) Presents Updated Phase I Data On BTK Inhibitor BGB-3111 In Patients With Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma At The 14th International Conference On Malignant Lymphoma     6/14/2017
Novartis AG (NVS) Drug Tasigna Receives EU Approval For Inclusion Of Treatment-Free Remission (TFR) Data In Product Label     6/6/2017
AbbVie (ABBV) Release: Long-Term IMBRUVICA (ibrutinib) Efficacy And Safety Data At ASCO 2017 Show Sustained Survival Rates In Up To Four Years In Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients, Including Those With High-Risk Disease     6/5/2017
TG Therapeutics (TGTX) Announces Follow-Up Data From The Chemo-Free Triple Combination Of TG-1101, TGR-1202, And Ibrutinib At The 53rd Annual Meeting Of The ASCO     6/5/2017
Janssen R&D Release: Data At ASCO Show Consistent Progression-Free Survival Benefit In Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated With Ibrutinib, Including Those With High-Risk Disease, With Up To Four Years Of Follow-Up     6/5/2017
AbbVie (ABBV) Release: New Data Presented At ASCO 2017 Finds IMBRUVICA (Ibrutinib) May Offer A More Targeted Approach To Chronic Lymphocytic Leukemia (CLL) Treatment Than Chemotherapy Agent Chlorambucil In Treatment-Naïve Patients     6/5/2017
MEI Pharma (MEIP) Announces Pre-Specified Response Rate Exceeded In Dose-Escalation Study Of ME-401 In Chronic Lymphocytic Leukemia And Follicular Lymphoma     5/31/2017
TG Therapeutics (TGTX) Announces Successful Outcome From Pre-Planned Interim Analysis By Independent DSMB In The UNITY-CLL Phase III Trial     5/23/2017
AbbVie (ABBV) Release: IMBRUVICA (Ibrutinib) Pooled Outcomes Data From Three Phase III Studies Suggest Potential Clinical Efficacy In Patients With High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)     5/15/2017
TG Therapeutics (TGTX) Rockets After Leukemia Drug Clears Hurdle in Late-Stage Study     3/6/2017

//-->